CP and acute lymphoblastic leukemia: This led to the Food and Drug Administration (FDA) accelerated approval in 2012 of ponatinib 45 mg daily for patients with CML post resistance or intolerance to other TKIs, and for Ph-positive ALL (full approval in 2016 for CML-CP or in transformation, and Ph-positive ALL when no other TKI is indicated, and for T315I-mutated disease) [106, 107].